NCT03880487View on ClinicalTrials.gov

A Single and Multiple Ascending Dose Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of KP-1199

PHASE1TerminatedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

March 12, 2019

Primary Completion Date

April 21, 2020

Study Completion Date

April 21, 2020

Conditions
Analgesia
Interventions
DRUG

KP-1199

Single dose and Multiple ascending doses of KP-1199 oral capsules

DRUG

Placebo oral capsule

Single dose and Multiple dose identical to active treatment but without KP-1199.

DRUG

Oxycodone oral capsule

10 mg Oxycodone Capsules

Trial Locations (1)

84124

PRA Health Sciences, Salt Lake City

Sponsors

Collaborators (1)

PRA Health Sciences
All Listed Sponsors
collaborator

United States Department of Defense

FED

collaborator

PRA Health Sciences

INDUSTRY

lead

Kalyra Pharmaceuticals, Inc.

INDUSTRY

NCT03880487 - A Single and Multiple Ascending Dose Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of KP-1199 | Biotech Hunter | Biotech Hunter